A well-informed asset strategy is an essential component of developing a novel therapy to meet critical patient needs.

Some people need to “think out loud.” Others are eager to get right to the point. Toss in challenging schedules and countless communication platforms…

The first edition of "Connecting the Dots" was published on September 29, 2017. Since Sue Nemetz penned that inaugural piece, 12 authors from our…

Biopharma companies need to balance many critical priorities, especially those that are pre-commercial.

As summer winds down and vacations (sadly) come to an end, it’s a natural time to shift focus toward the close of the calendar year. Business leaders…

The energy was palpable at the 2025 Medical Affairs Professional Society (MAPS) Global Annual Meeting. Conversations were expansive, workshops…

In our biopharma world, we frequently hear the term “Key Business Questions (KBQs).” And while it’s often thrown around as a buzzword (or buzz…

The value of New Product Planning (NPP) is often overlooked, but it plays a crucial role in the success of drug development projects. By…

How do we think about biopharma annual planning differently? The analogy we will draw on is fitness trackers and apps—built for mindfulness and…

In the biopharma industry, the Target Product Profile (TPP) is a critical tool for guiding the development and commercialization of new drugs.